Condition

Polycythemia Vera clinical trials and research

• 27Clinical trials
• 1NIH research projects
• 23Countries

Newest Polycythemia Vera clinical trials

All recruiting trials (27)

• MPNdpoint: Long-term Look at Philadelphia-negative Myeloproliferative Neoplasms

  This study tests how outcomes differ for patients 16 and older with polycythemia vera, essential thrombocythemia, or myelofibrosis by collecting and analyzing clinical and treatment data.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07863466

• Test of bomedemstat for polycythemia vera in adults

  This study tests bomedemstat (MK-3543) to see if it helps people with polycythemia vera reach healthier blood counts compared with standard treatments.

  Recruiting at 5 sites Phase 2/3 Merck Sharp & Dohme LLC · Newark, Delaware and 4 other locations · NCT07722611

• Rusfertide in Japanese adults with polycythemia vera

  This study tests rusfertide in Japanese adults with polycythemia vera to see if it helps keep hematocrit under control and reduce the need for blood removal.

  Recruiting at 8 sites Phase 2 Takeda · Nagoya, Aichi-ken and 8 other locations · NCT07648030

• Sapablursen added to standard care for people with polycythemia vera

  This trial will test whether adding sapablursen to standard therapy can reduce the need for phlebotomy in people with polycythemia vera who remain phlebotomy-dependent.

  Recruiting at 38 sites Phase 3 Ono Pharmaceutical Co., Ltd. · Orange, California and 37 other locations · NCT07429266

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• ELN multicenter analysis of phenotypic evolution and clinical outcomes

  This study tries to find features linked to JAK2V617F-positive essential thrombocythemia (ET) patients who later developed polycythemia vera (PV) by comparing them with matched ET patients who did not progress and with patients diagnosed with de novo PV.

  Recruiting at 10 sites FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · Rochester, Minnesota and 23 other locations · NCT07203768

• BEBT-507 Injection for Polycythemia Vera

  This study tests BEBT-507 to see if it is safe and possibly helpful for adults with polycythemia vera who have not responded well to standard therapies.

  Recruiting Phase 1 BeBetter Med Inc · Tianjin, Tianjin Municipality · NCT07012109

• Evaluating a new treatment for Polycythemia Vera

  This study is testing a new drug for people with Polycythemia Vera who haven't had success with standard treatments to see if it's safe and effective for them.

  Recruiting at 6 sites Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Zhengzhou, Henan and 5 other locations · NCT06752746

• Evaluating symptom burden in patients with Polycythemia Vera treated with ropeginterferon alfa-2b

  This study is testing how well ropeginterferon alfa-2b helps adults with Polycythemia Vera feel and function better while keeping track of their symptoms and treatment experiences.

  Recruiting iOMEDICO AG · Hanover, Lower Saxony · NCT06743035

• Evaluating Peginterferon for treating Essential Thrombocythemia and Polycythemia Vera

  This study is testing if a weekly injection of Peginterferon can help people with Essential Thrombocythemia and Polycythemia Vera feel better and stay safe while using the treatment.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06734637

• Comparing ASTX727 with and without Iadademstat for advanced blood cancers

  This study is testing whether adding iadademstat to the ASTX727 treatment can help people with advanced blood cancers feel better and live longer compared to just using ASTX727 alone.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 31 other locations · NCT06661915

• Observing the effects of ropeginterferon alfa-2b in patients with Polycythemia Vera

  This study is testing how well the drug ropeginterferon alfa-2b works and is tolerated by people with Polycythemia Vera who need treatment.

  Recruiting at 37 sites FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · Bergamo, Lombardy and 36 other locations · NCT06506084

• Evaluating GLB-001 for patients with myeloid malignancies

  This study is testing a new oral treatment called GLB-001 to see if it is safe and effective for people with certain types of blood cancers that have come back or didn't respond to other treatments.

  Recruiting at 14 sites Phase 1 Hangzhou GluBio Pharmaceutical Co., Ltd. · Hefei, Anhui and 13 other locations · NCT06378437

• Characterizing Monocytes in Blood Disorders

  This study is trying to learn more about the role of certain blood cells called monocytes in patients with specific blood disorders to see how they might affect the disease and treatment options.

  Recruiting University Hospital, Angers · Angers, Maine et Loire and 2 other locations · NCT06361641

• Evaluating the safety and effectiveness of bomedemstat for blood disorders

  This study is trying to see how safe and effective bomedemstat is for people with blood disorders like essential thrombocythemia and myelofibrosis who have been doing well on the treatment for at least six months.

  Recruiting at 18 sites Phase 3 Merck Sharp & Dohme LLC · Ann Arbor, Michigan and 20 other locations · NCT06351631

• Combining Pacritinib and Talazoparib for Patients with Myeloproliferative Neoplasms Not Responding to JAK2 Therapy

  This study is testing a combination of two medications, pacritinib and talazoparib, to see if they can help patients with certain blood cancers who haven't responded to other treatments.

  Recruiting Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT06218628

• Comparing givinostat and hydroxyurea for treating polycythemia vera

  This study is testing whether givinostat works better than hydroxyurea for treating high-risk polycythemia vera in patients with a specific genetic mutation.

  Recruiting at 72 sites Phase 3 Italfarmaco · Birmingham, Alabama and 89 other locations · NCT06093672

• Curcumin for treating inflammation and symptoms in blood disorders

  This study is testing if a curcumin supplement can help reduce inflammation and improve symptoms in people with certain blood disorders.

  Recruiting at 2 sites Phase 2 University of Southern California · Los Angeles, California and 1 other locations · NCT06063486

• Registry of Asian patients with myeloproliferative neoplasms

  This study is collecting information from Asian patients with myeloproliferative neoplasms to learn more about their condition and how different treatments work for them.

  Recruiting The University of Hong Kong · Hong Kong · NCT05882773

• Combining pegylated interferon α-2b with ruxolitinib for treating resistant polycythemia vera

  This study is testing if combining two medications, pegylated interferon α-2b and ruxolitinib, can help people with polycythemia vera who haven't responded well to other treatments feel better.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT05870475

• Comparing Apixaban and Rivaroxaban to Aspirin for Preventing Blood Clots in Certain Blood Disorders

  This study is testing whether the blood thinners Apixaban and Rivaroxaban can prevent blood clots better than low-dose aspirin in patients with certain blood disorders who are at high risk.

  Recruiting at 20 sites Phase 3 University Hospital, Brest · Angers and 41 other locations · NCT05198960

• Finding the best dose of N-Acetylcysteine for patients with blood disorders

  This study is testing the best dose of N-Acetylcysteine to see if it can help people with certain blood disorders feel better while they continue their usual treatments.

  Recruiting Phase 1/2 University of California, Irvine · Irvine, California and 1 other locations · NCT05123365

• Reduced-intensity conditioning to lower treatment-related mortality in stem cell transplant patients

  This study is testing a new way to prepare patients for a stem cell transplant to see if it can lower the risk of serious treatment-related complications.

  Recruiting Phase 2 Thomas Jefferson University · Philadephia, Pennsylvania · NCT05031897

• Using Ruxolitinib to treat symptoms of essential thrombocythemia and polycythemia vera

  This study is testing if the drug Ruxolitinib can help reduce symptoms for people with low-risk essential thrombocythemia and polycythemia vera.

  Recruiting at 3 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 3 other locations · NCT04644211

• Combining decitabine with ruxolitinib, fedratinib, or pacritinib for treating advanced myeloproliferative neoplasms

  This study is testing if combining decitabine with other medications can help patients with advanced blood cancers get ready for a stem cell transplant.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT04282187

• Comparing Ruxolitinib to Hydroxycarbamide or Interferon for High Risk Polycythemia Vera

  This study is testing whether ruxolitinib works better than hydroxycarbamide or interferon for people with high-risk polycythemia vera.

  Recruiting at 53 sites Phase 3 University of Birmingham · Aberdeen and 54 other locations · NCT04116502

• Registry for patients with myeloproliferative neoplasms

  This study is creating a database to gather information from people with myeloproliferative neoplasms to help improve treatments and outcomes for these rare blood cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT02760238

NIH-funded research (1)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• How bone marrow macrophages affect red blood cell production in polycythemia vera

  This project looks at whether certain bone marrow immune cells and their signals cause too many red blood cells and if blocking those signals could help people with polycythemia vera.

  NIH research New York Blood Center · Rye, UNITED STATES · NIH-11378743

Related topics

Quick answers

How many Polycythemia Vera clinical trials are recruiting right now?

27, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 23 countries. The most sites are in United States (13 trials), China (5 trials), Italy (5 trials), United Kingdom (5 trials), France (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 3: 5, Phase 1: 4, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →